The role of thromboprophylaxis in cancer patients: Emerging data

Current Opinion in Hematology

Volumn 17, Issue 5, 2010, Pages 450-456

  Menapace, Laurel A ^a   Khorana, Alok A ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

cancer; risk factors; thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTIANEMIC AGENT; ANTINEOPLASTIC AGENT; AVE 5026; BEVACIZUMAB; BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 8; C REACTIVE PROTEIN; CISPLATIN; D DIMER; DALTEPARIN; ENOXAPARIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; OXALIPLATIN; PADGEM PROTEIN; PROTHROMBIN; SEMULOPARIN; TAMOXIFEN; THALIDOMIDE; THROMBOPLASTIN; UNCLASSIFIED DRUG; WARFARIN;

BLEEDING; CANCER PATIENT; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDICATION; HUMAN; LEUKOCYTE COUNT; NEOPLASM; PANCREAS CANCER; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; THROMBOCYTE COUNT; THROMBOSIS PREVENTION; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

BIOLOGICAL MARKERS; FIBRINOLYTIC AGENTS; HUMANS; NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; VENOUS THROMBOEMBOLISM;

EID: 77955922816     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e32833c0760     Document Type: Review

References (38)

1. Heit JA, Silverstein MD, Mohr DN, et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000; 160:809-815.
2. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005; 293:715-722.
3. Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 1999; 78:285-291.
4. Khorana AA, Francis CW, CulakovaE, et al. Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol 2006; 24:484-490.
5. Khorana AA, Francis CW, Culakova E, et al. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer 2007; 110:2339-2346.
6. Spencer FA, Lessard D, Emery C, et al. Venous thromboembolism in the outpatient setting. Arch Intern Med 2007; 167:1471-1475.
7. Starling N, Rao S, Cunningham D, et al. Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: a report from the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group. J Clin Oncol 2009; 27:3786-3793.
8. Bennett CL, Angelotta C, Yarnold PR, et al. Thalidomide-and lenalidomide-associated thromboembolism among patients with cancer. JAMA 2006; 296:2558-2560.
9. Scappaticci FA, Skillings JR, HoldenSN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007; 99:1232-1239.
10. Nalluri SR, Chu D, Keresztes R, Zhu X. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 2008; 300:2277-2285.
11. Bennett CL, Silver SM, Djulbegovic B, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008; 299:914-924.
12. Khorana AA, Francis CW, Culakova E, Lyman GH. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer 2005; 104:2822-2829.
13. Khorana AA, Kuderer NM, Culakova E, et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111:4902-4907.
14. Simanek R, Vormittag R, Ay C, et al. High platelet count associated with venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). J Thromb Haemost 2010; 8:114-120.
15. Connolly G, Kuderer N, Francis CW, et al. Leukocytosis, thrombosis and mortality in cancer [abstract 1573]. In: XXII International Society of Throm bosis and Hemostasis Congress; 11-16 July 2009; Boston, Massachus-setts: J Thromb Haemost; 2009; 7:169-170.
16. Arpaia G, Carpenedo M, Verga M, et al. D-dimer before chemotherapy might predict venous thromboembolism. Blood Coagul Fibrinolysis 2009; 20:170-175.
17. Stender MT, Frokjaer JB, Larsen TB, et al. Preoperative plasma D-dimer is a predictor of postoperative deep venous thrombosis in colorectal cancer patients: a clinical, prospective cohort study with one-year follow-up. Dis Colon Rectum 2009; 52:446-451.
18. Kodama J, Seki N, Masahiro S, et al. D-dimer level as a risk factor for postoperative venous thromboembolism in Japanese women with gynecolo gic cancer. Ann Oncol 2010 [Epub ahead of print].
19. Ay C, Vormittag R, Dunkler D, et al. D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol 2009; 27:4124-4129.
20. Kasthuri RS, Taubman MB, Mackman N. Role of tissue factor in cancer. J Clin Oncol 2009; 27:4834-4838.
21. Manly DA, Wang J, Glover SL, et al. Increased microparticle tissue factor activity in cancer patients with venous thromboembolism. Thromb Res 2010; 125:511-512.
22. Zwicker JI, Liebman HA, Neuberg D, et al. Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malig nancy. Clin Cancer Res 2009; 15:6830-6840.
23. Bharthuar AAK, Mackman N, Hutson A, et al. Association of tissue factor with prothrombotic state in pancreaticobiliary cancer (PBC) [abstract]. In: 2010 Gastrointestinal Cancers Symposium; 2010 Jan 22-24; Orlando, FL. Abstract no. 158.
24. Kanz R, Ay C, Dunkler D, et al. Elevated C-reactive protein levels are associated with risk of occurrence of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study [abstract #OC-TU-013]. J Thromb Haemost 2009; 7:168.
25. Ay C, Simanek R, Vormittag R, et al. High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). Blood 2008; 112:2703-2708.
26. Vormittag R, Simanek R, Ay C, et al. High factor VIII levels independently predict venous thromboembolism in cancer patients: the cancer and throm bosis study. Arterioscler Thromb Vasc Biol 2009; 29:2176-2181.
27. Ay C, Chiriac AL, Dunkler D, et al. Biomarkers improve the risk scoring model for prediction of cancer-associated thrombosis [abstract #OC-TU-016]. J Thromb Haemost 2009; 7:169.
28. Palumbo A, Rajkumar SV, Dimopoulos MA, et al. Prevention of thalidomide-and lenalidomide-associated thrombosis in myeloma. Leukemia 2008; 22:414-423.
29. Wagman LD, Baird MF, Bennett CL, et al. Venous thromboembolic disease: clinical practice guidelines in oncology. J Natl Compr Canc Netw 2006; 4:838-869.
30. Lyman GH, Khorana AA, Falanga A, et al. American Society of Clinical Oncology Guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007; 25:5490-5505.
31. Agnelli G, Gussoni G, Bianchini C, et al. Nadroparin for the preven-tion of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol 2009; 10:943-949.
32. Palumbo A, Cavo M, Bringhen S, et al. A phase III study of enoxaparin vs aspirin vs low-dose warfarin as thromboprophylaxis for newly diagnosed myeloma patients treated with thalidomide based-regimens [abstract #492]. In: 51st ASH Annual Meeting and Exposition; 5-8 Dec. 2009; New Orleans, LA. Blood (ASH Annual Meeting Abstr) 2009;114.
33. Icli F, Akbulut H, Utkan G, et al. Low molecular weight heparin (LMWH) increases the efficacy of cisplatinum plus gemcitabine combination in advanced pancreatic cancer. J Surg Oncol 2007; 95:507-512.
34. Riess H, Pelzer U, Hilbig A, et al. Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy. BMC Cancer 2008; 8:361.
35. Riess UP, Deutschinoff G, Opitz B, et al. A prospective, randomized trial of chemotherapy with or without the low molecular weight heparin (LMWH) enox aparin in patients (pts) with advanced pancreatic cancer (APC): results of the CONKO 004 trial [abstract #LBA4506]. J Clin Oncol 2009; 27 (Suppl):18S.
36. Maraveyas MH, Lofts F, Garadi KK, et al. Chemoanticoagulation versus che motherapy in advanced pancreatic cancer (APC): results of the interim analysis of the FRAGEM trial [abstract #4583]. J Clin Oncol 2007; 25(Suppl):1 8S.
37. Maraveyas MH, Roy R, Propper D, et al. Gemcitabine with or without prophylactic weight adjusted dalteparin in patients with advanced or meta static pancreatic cancer (APC): a multicentre, randomised phase IIB trial (the UK FRAGEM study) [abstract]. Eur J Cancer Suppl 2009; 7.
38. Kuderer N, Ortel T, Khorana A, et al. Low molecular weight heparin thrombo-prophylaxis in ambulatory cancer patients: a systematic review and meta analysis of randomized controlled trials [abstract #490]. Blood (ASH Annual Meeting Abstr) 2009; 114.